RhuDex(R) Achieves Positive Results In Clinical Phase IIa Trial
Jun 30th 2008Drug InformationArthritis
Active Biotech AB’s (OMX Nordic:ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the candidate drug RhuDex® for the treatment of rheumatoid arthritis. In addition to positive safety data and the good adsorption after oral administration, a first indication of biological activity of RhuDex® was observed.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
